Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial

There is no consensus on the importance of visit-to-visit glycemic variability in diabetes. Therefore, we assessed the effects of visit-to-visit variability (VVV) in HbA1c and fasting glucose on major outcomes in the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Control...

Full description

Saved in:

Bibliographic Details
Published in:	Diabetes care Vol. 37; no. 8; p. 2359
Main Authors:	Hirakawa, Yoichiro, Arima, Hisatomi, Zoungas, Sophia, Ninomiya, Toshiharu, Cooper, Mark, Hamet, Pavel, Mancia, Giuseppe, Poulter, Neil, Harrap, Stephen, Woodward, Mark, Chalmers, John
Format:	Journal Article
Language:	English
Published:	United States 01.08.2014
Subjects:	Aged Aged, 80 and over Blood Glucose - analysis Blood Glucose - metabolism Cause of Death Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - mortality Diabetic Angiopathies - etiology Diabetic Angiopathies - mortality Drug Combinations Female Follow-Up Studies Gliclazide - therapeutic use Humans Hypoglycemic Agents - therapeutic use Indapamide - therapeutic use Male Middle Aged Office Visits - statistics & numerical data Perindopril - therapeutic use Risk Factors
ISSN:	1935-5548, 1935-5548
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!